Management of von Willebrand disease: a survey on current clinical practice from the haemophilia centres of North America

Autor: Barbara A. Konkle, Joseph Addiego, Benjamin Deulbesonic, George R. Buchanan, Brad Lewis, Linda G. Shaffer, Alton L. Lightsey, Ari J. Cohen, W. Keith Hoots, James L. Harper, John Bouhasin, Thomas H. Howard, Donald Mahoney, Gilbert C. White, Parvin Saidi, Carol K. Kasper, D. C. Talbert, Eric Larsen, David Lilligrap, Jack Lazerson, Martin J. Inwood, Bruce Ritchie, Elizabeth Kurczynski, Margaret Heisel, James Harper, J. Paul Scott, Robert L. Janco, Peter A. Kouides, Frederick Rickles, Alan Cohen, Anne Thomas, Indira Warrier, Prad Phatak, John D. Bouhasin, Cathy Rosenfield, S. R. Seitcher, David Green, Deborah L Brown, J. Heinreich Joist, Bridget Freeman, Mark Mancino, Edward H. Romond, Felicia Little, Leticia Valdez, Eric J. Werner, Patricia McCusker, Robert Bona, W. Paul Bowman, Louis Geeraerts, J. Teitel, Donna DiMichele, Catherine S. Manno, Jerry S. Powell, Bruce M. Ewenstein, Michael D. Tarantino, Dennis Gastineau, Richard Edwards, Thomas C. Abshire, Craig M. Kessler, Rachelle Nuss, Judy Wilimas, Gerald Gilchrist, Cindy Lessinger, Roshini Kulkarni, Jeannne M. Lusher, Margaret V. Ragni, Alberao Pappo, Sarah Hawk, Georges E. Rivard, Man Chiu Poon

Publikováno v: Haemophilia. 7:235-241

The optimal treatment of patients with von Willebrand's disease (vWD) remains to be defined. Moreover, it has not been firmly established which, if any, commonly measured parameters of von Willebrand factor (vWF) protein in the plasma are useful in g

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::28863ccf478d6797f6f55662e4ed5b60
https://doi.org/10.1046/j.1365-2516.2001.00498.x